Arcede Pharma
Arcede Pharma AB is a preclinical-stage Swedish pharmaceutical company developing RCD405, a patent-protected dual-mechanism (anti-inflammatory and bronchodilatory) drug candidate for COPD and severe asthma, operating under a virtual model and intending to monetize via licensing deals with global pharmaceutical partners.
- Company typePublic
- Founded2022
- HeadquartersLund, Sweden
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Arcede Pharma does
Arcede Pharma AB (publ) is a preclinical-stage Swedish pharmaceutical company headquartered at Medicon Village in Lund, founded in 2022 as a spin-out from Respiratorius AB (publ) to consolidate respiratory disease drug development projects. The company focuses on chronic obstructive pulmonary disease (COPD) and severe asthma, addressing a documented unmet need for new anti-inflammatory mechanisms given that current therapies only slow disease progression and are associated with serious side effects. Arcede's lead asset is RCD405, a drug candidate from the RESP9000 compound series that has demonstrated both anti-inflammatory and bronchodilatory properties in preclinical studies, distinguishing it from existing single-mechanism respiratory drugs. The company also retains the patent-protected RESP1000 compound series (granted in several countries) and the RESP3000 PET imaging program for cardiovascular diagnostics, though the latter two are not currently under active development.
The company's pipeline rests on proprietary medicinal chemistry inherited from Respiratorius, with patent applications for RESP9000 filed and patents granted for RESP1000 in several European countries. Toxicology studies on RCD405 were initiated in 2022 and the company prepared for Phase I clinical studies in 2023–2024 alongside scientific advisors from leading lung pharmacology institutions. Arcede operates a fully virtual organizational model with only the CEO as a direct employee, contracting external expertise on an as-needed basis across R&D, financial advisory (Västra Hamnen Corporate Finance), legal (Setterwalls Advokatbyrå), and capital markets administration (Nordic Issuing).
Arcede's revenue model is licensing-based: the company seeks a single enterprise strategic partner — a global pharmaceutical company with capital, clinical study expertise, and regulatory reach — to assume responsibility for late-stage development and commercialization. Expected income streams from such a deal are an upfront payment, development and regulatory milestone payments, and royalties on future sales. To date no licensing transaction has been announced, the company is pre-revenue, and funding to date has come from the 2022 Spotlight Stock Market listing, a 2023 preferential rights issue, and a January 2024 TO1 warrants exercise targeting approximately SEK 10 million for Phase I preparation. AGM materials from 2025 reference the company as "i likvidation" (in liquidation), indicating a material change in corporate trajectory after the primary data period.
Arcede Pharma firmographics
Firmographics- Name
- Arcede Pharma
- Legal name
- Arcede Pharma AB
- Website
- https://arcedepharma.com
- Company type
- Public
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Arcede Pharma AB is a preclinical-stage Swedish pharmaceutical company developing RCD405, a patent-protected dual-mechanism (anti-inflammatory and bronchodilatory) drug candidate for COPD and severe asthma, operating under a virtual model and intending to monetize via licensing deals with global pharmaceutical partners.
- Ownership category
- akta.pro rank
Arcede Pharma industry classification
Industry- Product category
- Respiratory Pharmaceutical Drug Development
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Pulmonary Hypertension & Rare Pulmonary Disease Therapies (HLAIAIAG)
- akta.pro secondary industries
- CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD), Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)
Keywords
Where Arcede Pharma is headquartered
LocationHeadquarters
- HQ city
- Lund
- HQ country
- Sweden
- HQ region
- Europe
Offices1 record
Markets served
Arcede Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Others
Revenue model
- Licensing and Milestone Payments: License agreements with pharmaceutical companies are expected to generate income in the form of an initial payment followed by milestone payments, as well as royalties on future sales.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Arcede Pharma product offering
Product offeringCore offering
Arcede Pharma develops patent-protected drug candidates with novel mechanisms of action for the treatment of chronic respiratory diseases, primarily chronic obstructive pulmonary disease (COPD) and severe asthma. The lead candidate RCD405, part of the RESP9000 compound series, has demonstrated combined bronchodilatory and anti-inflammatory properties in preclinical studies and was being prepared for Phase I clinical trials. The company operates a virtual development model and intends to monetize its pipeline through licensing agreements with pharmaceutical partners that assume responsibility for late-stage development, manufacturing, and commercialization.
Product overview
Arcede Pharma is a pharmaceutical company that operates a virtual development model focused on drug candidates for chronic respiratory diseases. The company is developing a portfolio of respiratory drug candidates with RCD405 as the lead product in the RESP9000 project, currently in preclinical development and preparing for Phase I clinical studies. Additional projects include RESP3000 for PET imaging diagnostics (currently inactive) and RESP1000 (inactive). The company seeks strategic partnerships with pharmaceutical companies for late-stage development and commercialization.
Differentiator
Problem solved
Functional benefit
Products and services
- RCD405 Lead drug candidate for the treatment of COPD and severe asthma. RCD405 is in preclinical phase and belongs to the RESP9000 project; it has demonstrated both anti-inflammatory and bronchodilatory properties and is the company's prioritized project for development of new medications.
- RESP9000 Compound series with a new mechanism of action demonstrating both anti-inflammatory and bronchodilatory properties. Contains RCD405 as the selected lead candidate plus additional undisclosed preclinical assets; patent applications submitted with patents granted in several European countries.
- RESP1000 Compound series of drug candidates with bronchodilatory and anti-inflammatory properties for the treatment of both COPD and asthma. Patents granted in several countries; no active research or development is being pursued on this project.
- RESP3000 PET imaging project for diagnosis of cardiovascular diseases. No active research or development is being pursued on this project; carried into Arcede Pharma from the Respiratorius pipeline at the 2022 spin-out.
Companies that use Arcede Pharma
Customer profileSegments2 records
Ideal customer profiles1 record
Arcede Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Arcede Pharma partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered minor and core.
- Clive PageminorProfessor Clive Page, Head of the Sackler Institute for Lung Pharmacology at King's College Hospital in London, engaged as advisor. Leading expert in lung pharmacology and lung medicine providing consultation on RCD405 project.
- Arne EgestenminorProfessor engaged as advisor to the RCD405 project. Leading expert in lung pharmacology and lung medicine.
- Setterwalls AdvokatbyråcoreLegal advisor to Arcede Pharma in connection with the Spotlight Stock Market listing.
- Respiratorius ABcoreParent company from which Arcede Pharma was spun out in 2022. Respiratorius shareholders received Arcede shares (1 Arcede share for every 50 Respiratorius shares).
Scale indicators3 records
Recent moves8 records
Expansion highlights5 records
Arcede Pharma competitors and assessment
Company assessmentBroad incumbents
- Almirall: European specialty pharma with a strong focus on respiratory and dermatology, historically an active in-licensor of early-stage respiratory assets — the archetype of a potential Arcede partner.
- Chiesi Farmaceutici: Private European pharmaceutical company with a large established respiratory franchise (ICS/LABA/LAMA products), representing the type of large-pharma partner Arcede targets for out-licensing deals.
Direct peers
- Theravance Biopharma: Specialty biopharma with a focused respiratory franchise (e.g., Yupelri) and a history of licensing arrangements with large pharma, mirroring Arcede's strategy of monetizing novel respiratory mechanisms through partnerships.
- Pulmatrix: Clinical-stage respiratory company developing inhaled therapies for COPD and other pulmonary diseases using proprietary dry-powder delivery, comparable in stage, size and therapeutic focus.
- Verona Pharma: Clinical-stage respiratory company developing ensifentrine, a first-in-class dual PDE3/PDE4 inhibitor for COPD maintenance treatment, with a direct out-licensing/CRO-driven model analogous to Arcede's.
- Synairgen: UK-listed respiratory biotech developing inhaled interferon-beta and other therapies for viral lung infections and COPD, with a similar small-cap, single-indication, licensing-oriented profile to Arcede.
- Respiratorius AB: Parent company from which Arcede was spun out in 2022; develops drug candidates for respiratory diseases including COPD and asthma using related RESP compound platforms, making it the closest direct peer.
Emerging players
- Aerami Therapeutics: Clinical-stage company developing inhaled therapies for severe respiratory diseases including pulmonary hypertension, with a similar inhaled-respiratory focus and licensing orientation to Arcede.
- Mereo BioPharma: Small-cap European biopharma with respiratory and rare-disease assets that has historically pursued partnership/out-license strategies for late-stage development, making it comparable in business model.
- Avalo Therapeutics: Small-cap biotech with inflammation/immunology assets, comparable in size and stage to Arcede and pursuing similar licensing-oriented value-creation strategies.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks7 records
Key highlights7 records
Customer concentration
Arcede Pharma social profiles
Digital presenceArcede Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Arcede Pharma leadership team
Management profileNumber of profiles
Profiles6 records
Arcede Pharma funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Arcede Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Arcede Pharma
What does Arcede Pharma do?
Arcede Pharma develops patent-protected drug candidates with novel mechanisms of action for the treatment of chronic respiratory diseases, primarily chronic obstructive pulmonary disease (COPD) and severe asthma. The lead candidate RCD405, part of the RESP9000 compound series, has demonstrated combined bronchodilatory and anti-inflammatory properties in preclinical studies and was being prepared for Phase I clinical trials. The company operates a virtual development model and intends to monetize its pipeline through licensing agreements with pharmaceutical partners that assume responsibility for late-stage development, manufacturing, and commercialization.
Is Arcede Pharma a public or private company?
Arcede Pharma is a public company. It is classified as public and is currently operating.
When was Arcede Pharma founded?
Arcede Pharma was founded in 2022. It employs 1 to 10 people.
Where is Arcede Pharma based?
Arcede Pharma is headquartered in Lund, Sweden, in the Europe region.
How does Arcede Pharma make money?
One revenue line is on record: licensing and Milestone Payments.
Who are Arcede Pharma's main competitors?
Broad incumbents on record are Almirall and Chiesi Farmaceutici. Direct peers are Theravance Biopharma, Pulmatrix, Verona Pharma, Synairgen and Respiratorius AB. Emerging players are Aerami Therapeutics, Mereo BioPharma and Avalo Therapeutics.
Does Arcede Pharma have an API?
No public API is recorded for Arcede Pharma.
What industry is Arcede Pharma in?
Arcede Pharma's product category is Respiratory Pharmaceutical Drug Development. Its primary akta.pro industry code is HLAIAIAG, Pulmonary Hypertension & Rare Pulmonary Disease Therapies, with a secondary code of HLAIALAD, CMC & Pharmaceutical Development (Formulation/Process/Analytical Development). Its NAICS code is 541714 and its SIC code is 2834.